Abstract:The development of a highly efficient, low-toxicity, ultrasmall ferrite nanoparticle-based T-1 contrast agent for high-resolution magnetic resonance imaging (MRI) is highly desirable. However, the correlations between the chemical compositions, in vitro T-1 relaxivities, in vivo nano-bio interactions and toxicities remain unclear, which has been a challenge in optimizing the in vivo T-1 contrast efficacy. Methods: Ultrasmall (3 nm) manganese ferrite nanoparticles (MnxFe3-xO4) with different doping concentrations of the manganese ions (x = 0.32, 0.37, 0.75, 1, 1.23 and 1.57) were used as a model system to investigate the composition-dependence of the in vivo T-1 contrast efficacy. The efficacy of liver-specific contrast-enhanced MRI was assessed through systematic multiple factor analysis, which included the in vitro T1 relaxivity, in vivo MRI contrast enhancement, pharmacokinetic profiles (blood half-life time, biodistribution) and biosafety evaluations (in vitro cytotoxicity testing, in vivo blood routine examination, in vivo blood biochemistry testing and H&E staining to examine the liver). Results: With increasing Mn doping, the T-1 relaxivities initially increased to their highest value of 10.35 mM(-1)s(-1), which was obtained for Mn0.75Fe2.25O4, and then the values decreased to 7.64 m M(-1)s(-1), which was obtained for the Mn1.57Fe1.43O4 nanoparticles. Nearly linear increases in the in vivo MRI signals (Delta SNR) and biodistributions (accumulation in the liver) of the MnxFe3-xO4 nanoparticles were observed for increasing levels of Mn doping. However, both the in vitro and in vivo biosafety evaluations suggested that MnxFe3-xO4 nanoparticles with high Mn-doping levels (x > 1) can induce significant toxicity. Conclusion: The systematic multiple factor assessment indicated that the MnxFe3-xO4 (x = 0.75-1) nanoparticles were the optimal T-1 contrast agents with higher in vivo efficacies for liver-specific MRI than those of the other compositions of the MnxFe3-xO4 nanoparticles. Our work provides insight into the optimization of ultrasmall ferrite nanoparticle-based T-1 contrast agents by tuning their compositions and promotes the translation of these ultrasmall ferrite nanoparticles for clinical use of high-performance contrast-enhanced MRI.

Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies

Magnetic Resonance Imaging Contrast Agent: Crgd-Ferric Oxide Nanometer Particle and Its Role in the Diagnosis of Tumor

Superparamagnetic Nanoparticles As High Efficiency Magnetic Resonance Imaging T2 Contrast Agent

Iron Oxide Nanoclusters for T 1 Magnetic Resonance Imaging of Non-Human Primates

Fabrication and Evaluation of Tumor-Targeted Positive MRI Contrast Agent Based on Ultrasmall MnO Nanoparticles.

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

Fe3O4 Nanoparticles Functionalized with Polymer Ligand for T-1-Weighted MRI in Vitro and in Vivo

Dysprosium-Modified Gold Nanoparticles as T 2ex Contrast Agents for Magnetic Resonance Imaging

Composition-Tunable Ultrasmall Manganese Ferrite Nanoparticles: Insights into their In Vivo T 1 Contrast Efficacy.

2, 3-Dimercaptosuccinic Acid-Modified Iron Oxide Clusters for Magnetic Resonance Imaging

Ultrasmall Water‐Soluble and Biocompatible Magnetic Iron Oxide Nanoparticles As Positive and Negative Dual Contrast Agents

Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging

In Vivo Evaluation of Innovative Gadolinium-Based Contrast Agents Designed for Bioimaging Applications

Gadolinium (III) oxide nanoparticles coated with folic acid-functionalized poly(β-cyclodextrin-co-pentetic acid) as a biocompatible targeted nano-contrast agent for cancer diagnostic: in vitro and in vivo studies

Periodic table screening for enhanced positive contrast in MRI and in vivo uptake in glioblastoma

A Contrast Examination of Proinflammatory Effects on Kidney Function for γ-Fe2O3 NP and Gadolinium Dimeglumine

Metallic Iron Nanoparticles for MRI Contrast Enhancement and Local Hyperthermia.

A T1/T2 dual functional iron oxide MRI contrast agent with super stability and low hypersensitivity benefited by ultrahigh carboxyl group density

Dysprosium-Modified Gold Nanoparticles As T2ex Contrast Agents for Magnetic Resonance Imaging

Magnetic PEGylated Pt3Co nanoparticles as a novel MR contrast agent: in vivo MR imaging and long-term toxicity study.